Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q2

4886.TEDINET S100PIUD
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥30.2bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥28.5bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥2.9bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥2.7bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥3.0bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.7bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥3.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥4.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥2.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.8bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income−¥2.8bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥86.2bnat 2022-09-30Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total assets¥78.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥34.2bnat 2022-09-30Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥52.0bnat 2022-09-30Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥41.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥17.2bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥17.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥10.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥199m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥427m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥83.182022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.252022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-98.522021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-137.172021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio60.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥114m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥86m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥28m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥20m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥473m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥231m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥30.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥30.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥3.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥93m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥66m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥26m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥342m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥229m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥25.6bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥25.6bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥28.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥28.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥26m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥3.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 470
ItemContextValueUnit
Capital stockCurrentQuarterInstant1197000000JPY
Capital surplusPrior1YearInstant1867000000JPY
Capital surplusCurrentQuarterInstant1847000000JPY
Retained earningsPrior1YearInstant45833000000JPY
Retained earningsCurrentQuarterInstant47954000000JPY
Treasury stockPrior1YearInstant-3479000000JPY
Treasury stockCurrentQuarterInstant-3375000000JPY
Shareholders equityPrior1YearInstant45419000000JPY
Shareholders equityCurrentQuarterInstant47624000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant3231000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant3739000000JPY
Foreign currency translation adjustmentPrior1YearInstant164000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant547000000JPY
Remeasurements of defined benefit plansPrior1YearInstant77000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant91000000JPY
Valuation and translation adjustmentsPrior1YearInstant3473000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant4378000000JPY
Net assetsPrior1YearInstant48892000000JPY
Net assetsCurrentQuarterInstant52002000000JPY
Liabilities and net assetsPrior1YearInstant83297000000JPY
Liabilities and net assetsCurrentQuarterInstant86227000000JPY
Net salesPrior1YTDDuration28477000000JPY
Net salesCurrentYTDDuration30172000000JPY
Cost of salesPrior1YTDDuration15051000000JPY
Cost of salesCurrentYTDDuration15870000000JPY
Gross profitPrior1YTDDuration13426000000JPY
Gross profitCurrentYTDDuration14301000000JPY
Selling general and administrative expensesPrior1YTDDuration10768000000JPY
Selling general and administrative expensesCurrentYTDDuration11422000000JPY
Operating incomePrior1YTDDuration2657000000JPY
Operating incomeCurrentYTDDuration2879000000JPY
Interest income noiPrior1YTDDuration0JPY
Interest income noiCurrentYTDDuration0JPY
Dividends income noiPrior1YTDDuration137000000JPY
Dividends income noiCurrentYTDDuration185000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration51000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration65000000JPY
Other noiCurrentYTDDuration51000000JPY
Non operating incomePrior1YTDDuration254000000JPY
Non operating incomeCurrentYTDDuration236000000JPY
Interest expenses noePrior1YTDDuration29000000JPY
Interest expenses noeCurrentYTDDuration25000000JPY
Expenses of inactive non current assets noePrior1YTDDuration108000000JPY
Expenses of inactive non current assets noeCurrentYTDDuration27000000JPY
Other noePrior1YTDDuration30000000JPY
Other noeCurrentYTDDuration75000000JPY
Non operating expensesPrior1YTDDuration168000000JPY
Non operating expensesCurrentYTDDuration128000000JPY
Ordinary incomePrior1YTDDuration2743000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass